A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders: The aphrodite project

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 227-233

  Vena, G A ^a   Galluccio, A ^b   De Simone, C ^c   Mastrandrea, V ^a   Buquicchio, R ^a   La Greca, S ^d   Dattola, S ^e   Puglisi Guerra, A ^f   Donato, L ^g   Cantoresi, F ^h   De Pita, O ⁱ   Pezza, M ^b   D'Agostino, M ^c   Vernaci, R ^e   Miracapillo, A ^j   Velenti, G ^k   Cassano, N ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Unit of Dermatology   (Italy)

^c Sacro Cuore Hospice   (Italy)

^d GARIBALDI HOSPITAL   (Italy)

^e Dermatology Unit   (Italy)

^f Ospedale Papardo   (Italy)

^g Dermatology Unit   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^j MIULLI GENERAL HOSPITAL   (Italy)

^k PUGLIESE CIACCIO HOSPITAL   (Italy)

more..

Author keywords

Adalimumab; Dose escalation; Psoriasis; Response; Treatment

Indexed keywords

ADALIMUMAB;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GINGIVITIS; HUMAN; HYPERGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; OPEN STUDY; PERICARDITIS; PLEUROPERICARDITIS; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; SIDE EFFECT; THROMBOCYTOSIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

EID: 62649149403     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200125     Document Type: Article

References (14)

1. Mease PJ, Gladman DD, Ritchlin CT, et al; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
2. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55:598-606.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106-15.
4. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-66.
5. Committee for medicinal products for human use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency London, 18 November 2004. http://www.emea.eu.int
6. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
7. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18:341-50.
8. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-57.
9. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57:269-75.
10. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46:529-32.
11. Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol 2007; 20:647-50.
12. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Rev Dermatol 2007; 2:335-49.
13. Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics: Targets & Therapy 2007; 1:93-103.
14. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921-6.